Why Adaptogenics Health Corp. (CSE: ADPT) Is ‘One to Watch’
Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertisements. Adaptogenics is pursuing three complementary opportunities across pharmaceutical-quality peptide supply, proprietary therapeutics and next-generation delivery technologies. Its planned supply network could generate commercial revenue while supporting therapeutic development through external manufacturing and laboratory partners. The company is targeting metabolic health, muscle preservation, mitochondrial function, recovery and healthy ageing through proprietary peptide and small-molecule therapeutics. CEO Dr. J. David Warren brings a scientific record that includes 17 issued patents, while President Antoun Nabhan brings experience spanning more than $2 billion in healthcare transactions and two Nasdaq IPO processes. Adaptogenics…
